Outcomes and prognostic factors in dogs with subcutaneous and intramuscular hemangiosarcoma treated with hypofractionated radiation therapy and chemotherapy.
- 1Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA, United States.
Abstract
Introduction
Subcutaneous (SC) and intramuscular (IM) hemangiosarcoma (HSA) in dogs are aggressive malignancies with high rates of recurrence and metastasis. Surgery is the primary treatment, but incomplete excision is common, and the role of radiation therapy (RT) remains unclear.Methods
This single-institution retrospective study evaluated outcomes and toxicities in dogs with SC and IM HSA treated with hypofractionated RT using either 24 Gy in three 8-Gy fractions (days 0, 7, and 21) or 30 Gy in five 6-Gy fractions every other day, with or without surgery and chemotherapy.Results
Fifty-three dogs were included: 27/53 (51%) SC HSA and 26/53 (49%) IM HSA; 35/53 (66%) had macroscopic disease at RT. Overall, 47/53 (89%) received chemotherapy, of which 42/47 (89%) received doxorubicin; 35/42 (83%) received it concurrently with the first RT fraction. Among 30 evaluable dogs, the RT objective response rate (ORR) was 93% (37% complete, 56% partial). Local progression or recurrence (LPR) occurred in 11/36 (30%) dogs after a median of 128 days, predominantly with macroscopic disease (10/11). Median time to progression (TTP) was not reached (95% CI, 621 days-not reached). In an exploratory multivariable Cox analysis, metastasis was associated with increased hazard of LPR (HR, 14.95; 95% CI, 2.84-78.72; p = 0.0014), whereas surgery was associated with a lower hazard, but not significantly (HR, 0.15; 95% CI, 0.018-1.24; p = 0.079). Overall median survival time (MST) was 306 days (95% CI, 284-875). On univariable analysis, anemia, absence of surgery, macroscopic disease at RT, metastasis, and tumor size at diagnosis >6 cm were associated with shorter survival. Dogs undergoing surgery prior to RT had longer survival (MST, 2059 vs. 287 days; p = 0.007). In multivariable analysis, anemia remained independently associated with increased hazard of death (HR, 3.20; 95% CI, 1.38-7.45; p = 0.0069), whereas metastasis, surgery, and tumor size were not independently associated with survival. Chemotherapy was not associated with survival. Radiation-associated adverse events were generally mild.Conclusion
Hypofractionated RT, as part of multimodal treatment in most dogs, was associated with a high ORR and may provide durable local control in dogs with non-visceral HSA.
Related
- Part 1 of a 2-part, open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 3 consecutive days of intramuscular and subcutaneous injections
- Economic and organizational impact of oral versus intravenous and subcutaneous administration of hypomethylating agents in patients with acute myeloid leukemia not eligible for intensive chemotherapy in Spain
- Prognostic value of the neutrophil-to-lymphocyte ratio in patients with colorectal cancer undergoing chemotherapy: a systematic review and meta-analysis
- Prognostic Significance of p53 Immunohistochemical Expression and Molecular Characterization of TP53 Variants in Triple-Negative Breast Cancer After Neoadjuvant Chemotherapy
- Clinical outcomes and prognostic factors of Ommaya reservoir-based intrathecal chemotherapy in lung cancer leptomeningeal metastasis: a retrospective cohort study
BibTeX
@article{rebelo2026outcomes,
title = {{Outcomes and prognostic factors in dogs with subcutaneous and intramuscular hemangiosarcoma treated with hypofractionated radiation therapy and chemotherapy.}},
author = {Ana Paula Rebelo and Adriana Furtado and Rance Sellon and Gregory D Roberts and Janean Fidel},
journal = {Frontiers in veterinary science},
year = {2026},
month = oct,
doi = {10.3389/fvets.2026.1925779},
url = {https://europepmc.org/article/MED/42903052},
note = {CC BY},
}
RIS
TY - JOUR
TI - Outcomes and prognostic factors in dogs with subcutaneous and intramuscular hemangiosarcoma treated with hypofractionated radiation therapy and chemotherapy.
AU - Ana Paula Rebelo
AU - Adriana Furtado
AU - Rance Sellon
AU - Gregory D Roberts
AU - Janean Fidel
PY - 2026
DA - 2026/10/06
JO - Frontiers in veterinary science
DO - 10.3389/fvets.2026.1925779
UR - https://europepmc.org/article/MED/42903052
AB - Introduction Subcutaneous (SC) and intramuscular (IM) hemangiosarcoma (HSA) in dogs are aggressive malignancies with high rates of recurrence and metastasis. Surgery is the primary treatment, but incomplete excision is common, and the role of radiation therapy (RT) remains unclear.Methods This single-institution retrospective study evaluated outcomes and toxicities in dogs with SC and IM HSA treated with hypofractionated RT using either 24 Gy in three 8-Gy fractions (days 0, 7, and 21) or 30 Gy in five 6-Gy fractions every other day, with or without surgery and chemotherapy.Results Fifty-three dogs were included: 27/53 (51%) SC HSA and 26/53 (49%) IM HSA; 35/53 (66%) had macroscopic disease at RT. Overall, 47/53 (89%) received chemotherapy, of which 42/47 (89%) received doxorubicin; 35/42 (83%) received it concurrently with the first RT fraction. Among 30 evaluable dogs, the RT objective response rate (ORR) was 93% (37% complete, 56% partial). Local progression or recurrence (LPR) occurred in 11/36 (30%) dogs after a median of 128 days, predominantly with macroscopic disease (10/11). Median time to progression (TTP) was not reached (95% CI, 621 days-not reached). In an exploratory multivariable Cox analysis, metastasis was associated with increased hazard of LPR (HR, 14.95; 95% CI, 2.84-78.72; p = 0.0014), whereas surgery was associated with a lower hazard, but not significantly (HR, 0.15; 95% CI, 0.018-1.24; p = 0.079). Overall median survival time (MST) was 306 days (95% CI, 284-875). On univariable analysis, anemia, absence of surgery, macroscopic disease at RT, metastasis, and tumor size at diagnosis >6 cm were associated with shorter survival. Dogs undergoing surgery prior to RT had longer survival (MST, 2059 vs. 287 days; p = 0.007). In multivariable analysis, anemia remained independently associated with increased hazard of death (HR, 3.20; 95% CI, 1.38-7.45; p = 0.0069), whereas metastasis, surgery, and tumor size were not independently associated with survival. Chemotherapy was not associated with survival. Radiation-associated adverse events were generally mild.Conclusion Hypofractionated RT, as part of multimodal treatment in most dogs, was associated with a high ORR and may provide durable local control in dogs with non-visceral HSA.
SN - 2297-1769
ER -